Royal Bank Of Canada Rigel Pharmaceuticals Inc Transaction History

Royal Bank Of Canada

  • $471 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Nov 05, 2024
BUY
$1.12 - $1.57 $4,564 - $6,397
4,075 New
4,075 $6,000
Q1 2024

May 15, 2024
SELL
$1.12 - $1.57 $56,952 - $79,834
-50,850 Reduced 92.58%
4,075 $6,000
Q4 2023

Feb 14, 2024
BUY
$0.72 - $1.56 $20,107 - $43,566
27,927 Added 103.44%
54,925 $79,000
Q3 2023

Nov 14, 2023
BUY
$1.07 - $1.39 $11,576 - $15,038
10,819 Added 66.87%
26,998 $29,000
Q2 2023

Aug 14, 2023
SELL
$1.12 - $1.82 $70,546 - $114,638
-62,988 Reduced 79.56%
16,179 $20,000
Q1 2023

May 15, 2023
SELL
$1.25 - $2.0 $206,087 - $329,740
-164,870 Reduced 67.56%
79,167 $104,000
Q4 2022

Feb 14, 2023
BUY
$0.67 - $11.9 $100,749 - $1.79 Million
150,372 Added 160.54%
244,037 $366,000
Q3 2022

Nov 14, 2022
BUY
$1.1 - $12.2 $97,502 - $1.08 Million
88,639 Added 1763.61%
93,665 $111,000
Q2 2022

Aug 15, 2022
SELL
$0.67 - $3.19 $7,016 - $33,405
-10,472 Reduced 67.57%
5,026 $6,000
Q1 2022

May 16, 2022
SELL
$2.22 - $3.45 $59,775 - $92,894
-26,926 Reduced 63.47%
15,498 $46,000
Q4 2021

Feb 14, 2022
BUY
$2.36 - $3.57 $46,942 - $71,010
19,891 Added 88.27%
42,424 $113,000
Q3 2021

Nov 15, 2021
BUY
$3.5 - $4.5 $22,172 - $28,507
6,335 Added 39.11%
22,533 $82,000
Q2 2021

Aug 16, 2021
BUY
$3.09 - $4.54 $50,051 - $73,538
16,198 New
16,198 $71,000

Others Institutions Holding RIGL

# of Institutions
8
Shares Held
334K
Call Options Held
0
Put Options Held
0
View Full List

About RIGEL PHARMACEUTICALS INC

RIGL Quotes by TradingView
  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email